Genmab Shares Fall After Reporting Q3 Results

MT Newswires Live11-07

Genmab (GMAB) shares were down almost 2% in recent Wednesday trading after the company reported its Q3 results.

Earlier, the drugmaker posted Q3 diluted earnings of 19.81 Danish kroner ($2.85), down from 31.94 Danish kroner a year earlier.

Analysts polled by Capital IQ expected 21.63 Danish kroner.

Revenue for the quarter ended Sept. 30 was 5.54 billion Danish kroner, up from 4.71 billion Danish kroner a year earlier.

Analysts polled by Capital IQ expected 5.65 billion Danish kroner.

Genmab said it now expects 2024 revenue of 21.10 billion to 21.70 billion Danish kroner, compared with 20.50 billion to 21.70 billion kroner previously. Analysts expect 20.88 billion Danish kroner.

Price: 22.36, Change: -0.39, Percent Change: -1.71

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481934722?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 02:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481934722","market":"sg","top_or_hot":-1,"title":"Genmab Shares Fall After Reporting Q3 Results","media":"MT Newswires Live","content":"<html><body><p> Genmab (GMAB) shares were down almost 2% in recent Wednesday trading after the company reported its Q3 results.</p><p>Earlier, the drugmaker posted Q3 diluted earnings of 19.81 Danish kroner ($2.85), down from 31.94 Danish kroner a year earlier.</p><p>Analysts polled by Capital IQ expected 21.63 Danish kroner.</p><p>Revenue for the quarter ended Sept. 30 was 5.54 billion Danish kroner, up from 4.71 billion Danish kroner a year earlier.</p><p>Analysts polled by Capital IQ expected 5.65 billion Danish kroner.</p><p>Genmab said it now expects 2024 revenue of 21.10 billion to 21.70 billion Danish kroner, compared with 20.50 billion to 21.70 billion kroner previously. Analysts expect 20.88 billion Danish kroner.</p><p>Price: 22.36, Change: -0.39, Percent Change: -1.71</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genmab Shares Fall After Reporting Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenmab Shares Fall After Reporting Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 02:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Genmab (GMAB) shares were down almost 2% in recent Wednesday trading after the company reported its Q3 results.Earlier, the drugmaker posted Q3 diluted earnings of 19.81 Danish kroner ($2.85), down ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481934722","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481934722","pubTimestamp":1730916141,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Genmab  shares were down almost 2% in recent Wednesday trading after the company reported its Q3 results.Earlier, the drugmaker posted Q3 diluted earnings of 19.81 Danish kroner , down from 31.94 Danish kroner a year earlier.Analysts polled by Capital IQ expected 21.63 Danish kroner.Revenue for the quarter ended Sept. 30 was 5.54 billion Danish kroner, up from 4.71 billion Danish kroner a year earlier.Analysts polled by Capital IQ expected 5.65 billion Danish kroner.Genmab said it now expects 2024 revenue of 21.10 billion to 21.70 billion Danish kroner, compared with 20.50 billion to 21.70 billion kroner previously. Analysts expect 20.88 billion Danish kroner.Price: 22.36, Change: -0.39, Percent Change: -1.71","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GMAB":"Genmab A/S"},"translate_title":"Genmab公布第三季度业绩后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMAB":0.9},"content_text":"Genmab (GMAB) shares were down almost 2% in recent Wednesday trading after the company reported its Q3 results.Earlier, the drugmaker posted Q3 diluted earnings of 19.81 Danish kroner ($2.85), down from 31.94 Danish kroner a year earlier.Analysts polled by Capital IQ expected 21.63 Danish kroner.Revenue for the quarter ended Sept. 30 was 5.54 billion Danish kroner, up from 4.71 billion Danish kroner a year earlier.Analysts polled by Capital IQ expected 5.65 billion Danish kroner.Genmab said it now expects 2024 revenue of 21.10 billion to 21.70 billion Danish kroner, compared with 20.50 billion to 21.70 billion kroner previously. Analysts expect 20.88 billion Danish kroner.Price: 22.36, Change: -0.39, Percent Change: -1.71","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481934722"}